| Literature DB >> 26385092 |
Jian Zhao1, Hui Wu1, Carl D Langefeld2, Kenneth M Kaufman3, Jennifer A Kelly4, Sang-Cheol Bae5, Graciela S Alarcón6, Juan-Manuel Anaya7, Lindsey A Criswell8, Barry I Freedman9, Diane L Kamen10, Gary S Gilkeson10, Chaim O Jacob11, Judith A James12, Joan T Merrill13, Patrick M Gaffney4, Kathy Moser Sivils14, Timothy B Niewold15, Michelle A Petri16, Seung Taek Song5, Hye-Jin Jeong5, Rosalind Ramsey-Goldman17, John D Reveille18, R Hal Scofield19, Anne M Stevens20, Susan A Boackle21, Luis M Vilá22, Deh-Ming Chang23, Yeong Wook Song24, Timothy J Vyse25, John B Harley3, Elizabeth E Brown26, Jeffrey C Edberg6, Robert P Kimberly6, Bevra H Hahn1, Jennifer M Grossman1, Betty P Tsao27, Antonio La Cava28.
Abstract
Leptin is abnormally elevated in the plasma of patients with systemic lupus erythematosus (SLE), where it is thought to promote and/or sustain pro-inflammatory responses. Whether this association could reflect an increased genetic susceptibility to develop SLE is not known, and studies of genetic associations with leptin-related polymorphisms in SLE patients have been so far inconclusive. Here we genotyped DNA samples from 15,706 SLE patients and healthy matched controls from four different ancestral groups, to correlate polymorphisms of genes of the leptin pathway to risk for SLE. It was found that although several SNPs showed weak associations, those associations did not remain significant after correction for multiple testing. These data do not support associations between defined leptin-related polymorphisms and increased susceptibility to develop SLE.Entities:
Keywords: Gene polymorphisms; Leptin pathway; Systemic lupus erythematosus
Mesh：
Substances：
Year: 2015 PMID： 26385092 PMCID： PMC4658308 DOI： 10.1016/j.clim.2015.09.007
Source DB: PubMed Journal: Clin Immunol ISSN： 1521-6616 Impact factor: 3.969